In April 2021, NextPharma took over Lonza’s plants in Ploërmel (France) and Edinburgh (UK). Next to these two newly acquired production facilities, NextPharma now has a total of five locations in Germany, one in France and one in Finland, and together with healthcare logistics services in the DACH region NextPharma continues to grow as a leading European organization for the development and production of pharmaceutical contracts (CDMO).

With exceptional expertise in the production of solid and semi-solid dosage forms and non-sterile and sterile liquids, this company provides a range of services, from pharmaceutical development, clinical stocks and process augmentation and validation to commercial production for a wide range of dosage forms including tablets, capsules, granules, powders, pellets, gels, creams, sprays and syrups, as well as a wide range of packaging solutions, including blowing, filling, sealing, blisters, bottles, bags, stick packaging and tubes.

With new acquisitions, NextPharma has added lipid-based formulations, such as Softgel, and liquid-filled hard shells for pharmaceutical, high-potency, hormonal, and food products to its services.